1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Src

Src

Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10363
    AP 24149
    Inhibitor
    AP 24149 is a potent Src-Abl dual inhibitor with IC50 values of 9.1, 3.6 nM for Src and Abl, respectively.
    AP 24149
  • HY-P3743
    p60c-src Substrate
    p60c-src Substrate is an efficient and specific substrate for p60c-src protein tyrosine kinase (PTK). p60c-src Substrate can be used to synthesize chimeric branched peptides.
    p60c-src Substrate
  • HY-112335
    Lck Inhibitor III
    Inhibitor
    Lck Inhibitor III (compound 12h) is a potent Lck inhibitor, with an IC50 of 867 nM. Lck Inhibitor III inhibits IL-2 synthesis in Jurkat cells, with an IC50 of 1.270 μM.
    Lck Inhibitor III
  • HY-121828
    TX-1123
    Inhibitor
    TX-1123 is a potent protein tyrosine kinase (PTK) inhibitor for Src, eEF2-K, and PKA, and EGFR-K/PKC. TX-1123 is a cyclo-oxygenase (COX) inhibitor with IC50 values of 1.16 μM and 15.7 μM for COX2 and COX1, respectively. TX-1123 has low mitochondrial toxicity. TX-1123 can be used in research of cancer.
    TX-1123
  • HY-P1377
    Caffeic acid-pYEEIE
    Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.
    Caffeic acid-pYEEIE
  • HY-N0701R
    (-)-Asarinin (Standard)
    Inhibitor
    (-)-Asarinin (Standard) is the analytical standard of (-)-Asarinin (HY-N0701). This product is intended for research and analytical applications. (-)-Asarinin is a tetrahydrofurofurano lignan with various biological activities. (-)-Asarinin induces apoptosis in cancer cells. (-)-Asarinin promotes mitochondrial ROS accumulation, inhibits the STAT3 signaling pathway and induces apoptosis in precancerous cells. (-)-Asarinin is a Src family kinase inhibitor that suppresses mast cell activation. (-)-Asarinin is a non-competitive Δ5-desaturase inhibitor with a Ki of 0.28 mM. (-)-Asarinin possesses pain relief, anti-viral, anti-allergic and anti-tuberculous bacilli, and anti-tumor effects.
    (-)-Asarinin (Standard)
  • HY-137918
    TGF-βRI inhibitor 3
    Inhibitor 99.16%
    TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC50 values of 13 μM and 0.63 μM for c-Src kinase and ALK5 kinase, respectively.
    TGF-βRI inhibitor 3
  • HY-W062835A
    CGP77675 hydrate
    Inhibitor
    CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity.
    CGP77675 hydrate
  • HY-172096
    cSRC/BCR-ABL-IN-1
    Inhibitor
    cSRC/BCR-ABL-IN-1 (compound 21b) is a potent Bcr-Abl and C-Src inhibitor with IC50 values of 56.2, 101 nM for Bcr-Abl, C-Src, respectively. cSRC/BCR-ABL-IN-1 shows cytotoxicity activity.
    cSRC/BCR-ABL-IN-1
  • HY-162291
    Lck-IN-3
    Inhibitor
    Lck-IN-3 (compound 7m) is an LCK inhibitor targeting acute lymphoblastic leukemia (ALL) that inhibits LCK phosphorylation. Lck-IN-3 can induce cell cycle arrest in the G2/M phase, leading to apoptosis in ALL cells.
    Lck-IN-3
  • HY-161687
    Cisplatin/Dasatinib prodrug-1
    Inhibitor
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively.
    Cisplatin/Dasatinib prodrug-1
  • HY-P0200
    RR-SRC
    RR-SRC is a substrate for src-tyrosine-specific protein kinase.
    RR-SRC
  • HY-146014
    Multi-kinase-IN-1
    Inhibitor
    Multi-kinase-IN-1 (Compound 11k) is a potent kinase inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell apoptosis, and can be studied for colorectal cancer.
    Multi-kinase-IN-1
  • HY-E70726
    FYN Y531F Recombinant Human Active Protein Kinase
    FYN Y531F Recombinant Human Active Protein Kinase is an oncogene that directly activated YANK2 through phosphorylation its Y110, and Fyn-mediated YANK2 phosphorylation at Y110 site promotes glioma growth by increasing its stability.
    FYN Y531F Recombinant Human Active Protein Kinase
  • HY-157290
    HL403
    Inhibitor
    HL403 is a potent and dual BRD4/Src inhibitor. HL403 has IC50 values of 133 nM for BRD4 inhibition and 4.5 nM for Src inhibition. HL403 shows anti-cancer activity.
    HL403
  • HY-108487
    N-Acetyl-O-phosphono-Tyr-Glu dipentylamide
    Inhibitor
    N-Acetyl-O-phosphono-Tyr-Glu dipentylamide (Ac-Tyr-Glu-N(n-C5H11)2), a dipeptide, is a pp60c-src SH2 domain inhibitor. N-Acetyl-O-phosphono-Tyr-Glu dipentylamide can be used for cancer research.
    N-Acetyl-O-phosphono-Tyr-Glu dipentylamide
  • HY-P1200A
    Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA
    Inhibitor
    Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions.
    Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA
  • HY-P2372
    P60v-src(137-157)
    Inhibitor
    P60v-src(137-157) is a synthetic peptide that inhibits the tyrosine kinase activity of p60v-src (IC50: 7.5 μM).
    P60v-src(137-157)
  • HY-177272
    HPK1-IN-61
    Inhibitor
    HPK1-IN-61 (Compound 1) is an inhibitor of hematopoietic progenitor kinase 1 (HPK1) (Ki = 0.4 nM) and an inhibitor of Abl (IC50 < 0.51 nM). HPK1-IN-61 also shows inhibitory activity againstLCK with an IC50 of 24 nM.
    HPK1-IN-61
  • HY-13314A
    Tesevatinib tosylate
    Inhibitor
    Tesevatinib (XL-647) tosylate is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib tosylate significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib tosylate also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib tosylate can inhibit tumor proliferation and exhibits antitumor activity.
    Tesevatinib tosylate
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.